130 related articles for article (PubMed ID: 25752654)
1. The timing of autologous stem cell transplantation and the prognostic factors affecting the prognosis in children with relapsed Hodgkin lymphoma.
Ataş E; Kesik V; Babacan O; Korkmazer N; Akyüz C
Pediatr Transplant; 2015 Jun; 19(4):380-4. PubMed ID: 25752654
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
4. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF
Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].
Jin FY; Zou DH; Wang GR; Xu Y; Feng SZ; Zhao YZ; Han MZ; Yan WW; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):645-8. PubMed ID: 16620547
[TBL] [Abstract][Full Text] [Related]
6. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM
Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708
[TBL] [Abstract][Full Text] [Related]
7. Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Eroglu C; Kaynar L; Orhan O; Keklik M; Sahin C; Yildiz OG; Mentes S; Kurnaz F; Aslan D; Sivgin S; Soyuer S; Eser B; Cetin M; Unal A
Am J Clin Oncol; 2015 Feb; 38(1):68-73. PubMed ID: 23563207
[TBL] [Abstract][Full Text] [Related]
8. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
[TBL] [Abstract][Full Text] [Related]
9. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
[TBL] [Abstract][Full Text] [Related]
11. Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplant.
Goda JS; Massey C; Kuruvilla J; Gospodarowicz MK; Wells W; Hodgson DC; Sun A; Keating A; Crump M; Tsang RW
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e329-35. PubMed ID: 22672755
[TBL] [Abstract][Full Text] [Related]
12. Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey.
Sucak GT; Çakar MK; Suyanı E; Akı Z; Altındal Ş; Acar K
Hematology; 2013 Sep; 18(5):269-76. PubMed ID: 23394351
[TBL] [Abstract][Full Text] [Related]
13. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.
Morschhauser F; Brice P; Fermé C; Diviné M; Salles G; Bouabdallah R; Sebban C; Voillat L; Casasnovas O; Stamatoullas A; Bouabdallah K; André M; Jais JP; Cazals-Hatem D; Gisselbrecht C;
J Clin Oncol; 2008 Dec; 26(36):5980-7. PubMed ID: 19018090
[TBL] [Abstract][Full Text] [Related]
14. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
Perz JB; Giles C; Szydlo R; O'Shea D; Sanz J; Chaidos A; Wagner S; Davis J; Loaiza S; Marin D; Apperley J; Olavarria E; Rahemtulla A; Lampert I; Naresh K; Samson D; MacDonald D; Kanfer EJ
Bone Marrow Transplant; 2007 Jan; 39(1):41-7. PubMed ID: 17115062
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma.
Akhtar S; El Weshi A; Rahal M; Abdelsalam M; Al Husseini H; Maghfoor I
Bone Marrow Transplant; 2010 Mar; 45(3):476-82. PubMed ID: 19734949
[TBL] [Abstract][Full Text] [Related]
16. [Clinical outcome of autologous stem cell transplantation as first-line treatment in 30 patients with high risk lymphoblastic lymphoma].
Huang W; Zou D; Sui W; Wang T; Fu M; Li Z; Xu Y; Zhao Y; Feng S; Han M; Qiu L
Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):332-6. PubMed ID: 24759023
[TBL] [Abstract][Full Text] [Related]
17. Managing relapsed and refractory Hodgkin lymphoma.
Brice P
Br J Haematol; 2008 Apr; 141(1):3-13. PubMed ID: 18279457
[TBL] [Abstract][Full Text] [Related]
18. High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma.
Persky DO; Moskowitz CH; Filatov A; Saxena R; Cui H; Teruya-Feldstein J
Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):35-40. PubMed ID: 19701081
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.
Nagle SJ; Woo K; Schuster SJ; Nasta SD; Stadtmauer E; Mick R; Svoboda J
Am J Hematol; 2013 Oct; 88(10):890-4. PubMed ID: 23813874
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.
Sureda A; Constans M; Iriondo A; Arranz R; Caballero MD; Vidal MJ; Petit J; López A; Lahuerta JJ; Carreras E; García-Conde J; García-Laraña J; Cabrera R; Jarque I; Carrera D; García-Ruiz JC; Pascual MJ; Rifón J; Moraleda JM; Pérez-Equiza K; Albó C; Díaz-Mediavilla J; Torres A; Torres P; Besalduch J; Marín J; Mateos MV; Fernández-Rañada JM; Sierra J; Conde E;
Ann Oncol; 2005 Apr; 16(4):625-33. PubMed ID: 15737986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
